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The C-3 phenolic hydroxy group containing morphine derivatives (morphine, oxymorphone, naloxone,
naltrexone) are excellent candidates for the synthesis of 3-O-functionalized molecules. Achieving free
carboxylic group containing derivatives gives the opportunity for further modification and conjugation that
could be used for immunization and immunoassays. For this purpose ethyl bromo- and chloroacetate can be
used as O-alkylating agents. Hydrolyzing the products affords the appropriate free carboxylic group containing
3-O-carboxyalkyl derivatives. As these molecules contain an acidic and a basic functional group the
protonation macro- and microconstants were determined too, using pH-potentiometry and NMR-pH titration,
beside fully characterizing their structure using IR, CD, NMR and HR-MS measurements.
Keywords: morphine, O ligands, hapten, protonation, NMR spectroscopy.
Introduction
The C-3 phenolic hydroxy group in morphine deriva-
tives is an important structural feature for analgesic
activity. O-Alkylation of this hydroxy group results in
compounds (codeine, ethylmorphine) which are less
potent than morphine. However, codeine is used as
analgesic to relieve mild to moderate pain besides
possessing antitussive activity.
Numerous O-alkylated derivatives of morphine
have been prepared and the C-3 carboxymethyl ether
proved to be very important in the development of
radioimmunoassay of morphine. One of the very first
3-O-derivatives of morphine was reported by Spector
and Parker which was a 3-O-alkylated compound.[1,2]
Morphine base was treated with sodium chloroace-
tate in ethanol to obtain 3-O-carboxymethylmorphine
(2-(morphin-3-O-yl)acetic acid) (Scheme 1). The prod-
uct did not have any analgesic effect but coupling
with bovine serum albumin (BSA) was possible in the
presence of 1-ethyl-3-(dimethylaminopropyl)
carbodiimide. The conjugate was immunogenic and it
was used for the quantitative determination of
morphine. Rabbits were immunized and blood was
collected after two months. To follow the binding
and inhibition of morphine to the antigens [3H]-
dihydromorphine was used. Both the radioactive and
nonradioactive molecules show competitive binding
to the antibodies present in the antisera. Using
known amount of labeled and unlabeled morphine a
standard curve can be obtained and determination of
unknown quantities of morphine is possible. This
method allowed the determination of morphine in
Supporting information for this article is available on the
WWW under https://doi.org/10.1002/cbdv.202100135 Scheme 1. Synthesis of 2-(morphin-3-O-yl)acetic acid.
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biological fluids without the necessity of extraction
procedures. The assay is very sensitive for morphine,
in serum 50 to 100 picograms of morphine can be
determined in 0.5 mL assay mixture. Rubinstein and
Ullman prepared the same conjugate but used the
mixed anhydride method with isobutyl
chloroformate.[3]
Buechler boiled morphine with bromoacetic acid
in ethanol to obtain 2-(morphin-3-O-yl)acetic acid.[4]
Heimann et al. treated the ethanol solution of
potassium morphinate with ethyl bromoacetate. The
received ethyl 2-(morphin-3-O-yl)acetate was hydro-
genated in the presence of Pd/C catalyst and after
hydrolysis 2-(dihydromorphin-3-O-yl)acetic acid was
obtained.[5]
Gandhi et al. treated the acetonitrile solution of 6-
monoacetylmorphine with chloroacetic acid in the
presence of sodium hydroxide.[6] 6-O-Acetyl ester of
2-(morphin-3-O-yl)acetic acid was coupled to bovine
serum albumin and this immunogen generated anti-
bodies against heroin and its metabolites. The anti-
body was labelled with fluorescein isothiocyanate in
order to develop a fluorescence immunoassay. Heroin
and its metabolites can be measured in biofluids up
to 0.01 ng/mL concentrations.
Ethyl 2-(morphin-3-O-yl)acetate was synthesized
by Heiman, Raden and Dubler.[5] In their patent
morphine was dissolved in absolute ethanol and
treated with potassium ethoxide. Ethyl bromoacetate
was added and after the reaction the product was
purified using preparative thin layer chromatography.
This compound later was used by Spiehler,[7]
Spector,[8] Findlay[9] and Hand[10] for quantitative
measurement of morphine and its metabolites, using
various immunoassay methods.
All of the so far mentioned derivatives possess the
ability to conjugate them to a bigger carrier molecule
and induce immune reaction. Hence these are
haptens by definition. Drug molecules solely do not
induce the defense of the immune system. Haptens
are still not immunogenic, however, these com-
pounds have the structural moiety (carboxylic/amino
group) to conjugate them to antigenic carrier mole-
cules such as proteins, lipids, or polysaccharides. This
gave the idea of vaccination against drug abuse that
could be an alternative therapy beside the meth-
adone protocol.[11,12] The successful application of
these conjugate vaccines mainly relies on hapten
design and density, coupling strategy and selection
of carrier protein along with vaccine adjuvant.[13,14]
A new trend can be observed in the case of
functionalization of the aromatic ring. Replacing the
phenolic hydroxy group with an isosteric amino
group leads to amides. These derivatives are more
resistant against hydrolysis than the ester equiva-
lents. The synthesis and conjugation of these amide
haptens to tetanus toxoid was reported by Li et al.[15]
PrOxyHap is a C3 amino group containing hapten
acylated with β-mercaptopropionic acid and the C6
position is modified into a 2-oxopropyl moiety (Fig-
ure 1). After tetanus-toxoid conjugation mice were
immunized. The antinociceptive effects of heroin,
morphine and 6-O-acetylmorphine were inhibited in
the animals by antigens.
Other heroin-like haptens were designed by
Matyas et al.[16] One of these compounds is the 3-
amino group containing 6-O-acetylmorphine deriva-
tive called 6-AcMorhap. The amino group is acylated
with β-mercaptopropionic acid, just like in PrOxyHap.
6-AcMorHap produced high titers of antibodies in
mice along with other derivatives.
During the metabolism of morphine and its
derivatives functionalization of the 3-OH group could
happen while 3-O-glucuronides are formed. All of
these metabolites are amphoteric as they contain
originally a tertiary amino group and as a result of
glucuronide conjugation a free carboxylic group, too.
Although these metabolites are not as active as the
parent molecules, they still possess some pharmaco-
logical effects. Moreover, they can be used for
immunoanalytical purposes to determine the amount
of morphine in urine.[17,18]
Our research team has recently published the
synthesis and characterization of acid-base properties
of N-carboxyalkyl and N-acetylglycine morphine
derivatives.[19] The purpose of the recent work was to
extend our studies for the synthesis of 3-O-
carboxymethyl derivatives. These functionalized com-
pounds contain basic tertiary nitrogen and free
carboxylic groups, so we intended to determine their
ionization constants, too. The synthesized molecules
are not only potential candidates for different type of
immunoassays but also show similarity to morphine-
Figure 1. PrOxyHap and 6-AcMorHap.
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The synthesis of 3-O-functionalized morphine deriva-
tive haptens was designed. For this purpose mor-
phine (1), oxymorphone (2), naloxone (3) and naltrex-
one (4) were selected as starting materials.
Metallic sodium was dissolved in absolute ethanol
and morphine hydrochloride salt was added to obtain
the sodium salt of morphine. Then it was mixed with
ethyl bromoacetate and refluxed for 6 h. The con-
version of the reaction was monitored by thin layer
chromatography (TLC). After the work-up process,
ethyl 2-(morphin-3-O-yl)acetate (5) was isolated
(Scheme 2).
Treatment of oxymorphone with ethyl chloroace-
tate in acetone solution for 12 h reflux in the
presence of potassium carbonate and potassium
iodide yielded ethyl 2-(oxymorphon-3-O-yl)acetate (6)
(Scheme 3).
The preparation method of naloxone derivative
was identical with that of oxymorphone. After
dissolving the base in acetone ethyl chloroacetate
was added in the presence of potassium carbonate
and potassium iodide and the mixture was refluxed
for 12 h (Scheme 4). After work-up, ethyl 2-(naloxon-
3-O-yl)acetate (7) was obtained.
The same reaction was accomplished with naltrex-
one (Scheme 5). The product was ethyl 2-(naltrexon-3-
O-yl)acetate (8).
All of the esters were hydrolyzed in the same way.
The compounds were dissolved in a minimal amount
of ethanol, the solutions were stirred and heated with
aqueous sodium hydroxide. After conversion was
complete the pH was adjusted to 2–3 and the
products were obtained as hydrochloride salts
(Scheme 6).
Structures of the products were confirmed with
1D and 2D NMR measurements along with HR-MS
analysis. The chemical shifts of the new side chains
are summarized in Table 1.
Circular dichroism (CD) spectroscopy is widely
used in the analysis of proteins and small molecule
pharmaceuticals. Several opium alkaloids were char-
acterized by Purdie et al. using CD.[20] Characteristic
structural bands can be easily observed on the
morphine and naloxone spectra. Approximately at
300 nm the negative band of n-π* transition of the
C-6 oxo derivative can be detected. The allyl group of
naloxone and cyclopropylmethyl group of naltrexone
do not have significant effect on the spectra. Around
at 240 nm and 275 nm a positive band-pair can be
Scheme 2. Synthesis of ethyl 2-(morphin-3-O-yl)acetate.
Scheme 3. Synthesis of ethyl 2-(oxymorphon-3-O-yl)acetate.
Scheme 4. Synthesis of ethyl 2-(naloxon-3-O-yl)acetate.
Scheme 5. Synthesis of ethyl 2-(naltrexon-3-O-yl)acetate.
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observed. The intensity and ratio of these are differ-
ent in the synthesized derivatives: in the esters the
peak is higher at 270 nm, while in the acids it is
higher at 240 nm.
In the case of the C-6 hydroxy group containing
morphine derivatives a weak band appears in the 1Lb
range of π-π* transition that can be assigned to the
substituted aromatic ring around 285 nm. Based on
the theoretical background of the sign of Lb-band
described by Snatzke, alkaloids with morphine skel-
eton have negative sign.[21] Furthermore an 1La π-π*
transition can be assigned to the substituted aro-
matic system, too. The presence of these bands and
comparing them to the standard spectra give
unambiguous evidence to the structural analogy.
At the range of 210–218 nm a characteristic p-
band for the aromatic ring is present in every
derivative.
Protonation Constants
The pharmacokinetic behavior of biomolecules and
drugs are influenced by several physicochemical
properties, the most important ones are the acid-
base character, lipophilicity, permeability, and
solubility.[22] The ionization state of a molecule in
solution is determined by its acid-base character and
the pH of the solution. In turn, the ionization state
influences all pharmacokinetic properties.[23]
3-O-carboxymethyl-opioid compounds with a free
carboxy site have two basic functional groups,
namely a carboxylate and an amino group, and can
occur in four different microscopic protonation forms
in solution. Such compounds are anionic in alkaline
solutions and upon protonation are converted into
either a zwitterionic or an uncharged form. These two
forms, differing from each other only in the site of
protonation, are called protonation isomers. The
second protonation step produces a cation. These
four microscopic protonation forms and the respec-
tive protonation microconstants are shown in
Scheme 7 on the example of 2-(morphin-3-O-yl)acetic
acid.
Protonation Macroconstants of 3-O-haptens
We have recently investigated N-carboxymethyl
opioid compounds,[19] where we showed that the
basicity of the carboxylate site is smaller by several
orders of magnitude than that of the amino site, thus
K2 values of the dibasic 3-O-carboxymethyl com-
pounds characterize almost exclusively the protona-
tion of the carboxylate sites, with K2 practically equal
to kCN.
The determination of protonation constants is
usually carried out by pH-potentiometry.[24] We also
used this method to obtain the protonation constants
of 3-O-haptens. However, log K2 values proved to be
too small, so we carried out NMR-pH titrations, where
the exact pH in highly acidic solutions was shown by
indicator molecules.
Scheme 6. Hydrolysis of 3-O-hapten esters.










Ethyl 2-(morphin-3-O-yl)acetate (5) 4.72/66.2 169.5 2-(Morphin-3-O-yl)acetic acid HCl (9) 4.75/68.9 176.5
Ethyl 2-(oxymorphon-3-O-yl)acetate (6) 4.82/65.9 169.2 2-(Oxymorphon-3-O-yl)acetic acid HCl (10) 4.81/69.4 177.0
Ethyl 2-(naloxon-3-O-yl)acetate (7) 4.81/65.8 168.6 2-(Naloxon-3-O-yl)acetic acid HCl (11) 4.82/69.5 176.8
Ethyl 2-(naltrexon-3-O-yl)acetate (8) 4.77/65.7 168.7 2-(Naltrexon-3-O-yl)acetic acid HCl (12) 4.79/69.5 177.2
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Although these compounds possess around
twenty protons, the chemical shift of only those
protons changes significantly in the acidic pH region
that are in the vicinity of the carboxy group. We
typically followed the doublets of the aromatic H1
and H2 protons and the signals of the methylene
protons in the carboxymethyl side chain.
The NMR-pH titration curve of 2-(morphin-3-O-yl)
acetic acid can be seen in Figure 2 and Figure 3.
The protonation macroconstants are shown in
Table 2.
Scheme 7. The microscopic protonation forms and microspecies of 2-(morphin-3-O-yl)acetic acid.
Figure 2. NMR-pH titration curves of the H2 and H1 aromatic
protons of 2-(morphin-3-O-yl)acetic acid. Computer fits for log
K2 are shown in solid lines.
Table 2. Protonation macroconstants of the investigated 3-O-haptens. The standard deviations are in parentheses.
logK1 logK2
2-(Morphin-3-O-yl)acetic acid (9) 8.32 (0.03) 2.94 (0.02)
Ethyl 2-(morphin-3-O-yl)acetate (5) 8.22 (0.04)
2-(Oxymorphon-3-O-yl)acetic acid (10) 9.00 (0.04) 2.86 (0.03)
Ethyl 2-(oxymorphon-3-O-yl)acetate (6) 8.87 (0.03)
2-(Naloxon-3-O-yl)acetic acid (11) 8.35 (0.03) 2.93 (0.03)
Ethyl 2-(naloxon-3-O-yl)acetate (7) 8.23 (0.04)
2-(Naltrexon-3-O-yl)acetic acid (12) 9.28 (0.04) 3.00 (0.04)
Ethyl 2-(naltrexon-3-O-yl)acetate (8) 9.13 (0.03)
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Protonation Microconstants of 3-O-haptens
The dibasic compounds possess a carboxylate and a
much more basic amino group; thus the deductive
method is needed for the determination of protona-
tion microconstants. This method makes use of a
model compound to mimic a microspecies on the
minor protonation pathway.[23] The kNC microconstants
of the dibasic 3-O-haptens can be mimicked by the
macroconstants of their esters. Using this micro-
constant and the already known two macroconstants,
the remaining three microconstants can be calculated
for the dibasic 3-O-haptens (Table 3). Table 3 also
contains the logEC,N pair-interactivity parameter that
shows to what degree the protonation of a basic
group decreases the basicity of the other group.
logEC;N ¼ logk
N   logkNC ¼ logk
C   logkCN (1)
As the basicity of the amino group is larger by
several orders of magnitude than that of the carbox-
ylate group, the upper protonation pathway of
Scheme 7 is the dominant one, and the concentration
of the zwitterionic species is much larger than that of
the uncharged one. The concentration of the micro-
species of the dominant protonation pathway can be
shown in distribution diagrams, exemplified here for
2-(morphin-3-O-yl)acetic acid (Figure 4).
The intersections of the species distribution curves
indicate that below pH 2.94 the cationic, above
pH 8.32 the anionic form is dominant, whereas in-
between this compound can mainly be found in the
zwitterionic form.
The basicity of the carboxylate site is similar in
each molecule, the largest difference is 0.16 in log
units. The similar basicity can be explained by the
fact that this group is located far away from the
opioid skeleton, where the investigated compounds
differ from each other. On the other hand, the
basicity of the amino site shows larger variations, the
largest difference is 0.96 in log units. The differences
in the basicity of the amino groups can be explained
by inductive and field effects from moieties situated
in the vicinity. The replacement of the N-methyl
group with an N-allyl one lowers the basicity of the
amino group in the oxymorphone-naloxone pair, but
the cyclopropylmethyl substituent causes the oppo-
site effect in the oxymorphone-naltrexone pair. The
Figure 3. Chemical shifts of the H2 and H1 aromatic protons of
2-(morphin-3-O-yl)acetic acid during NMR-pH titration.
Table 3. Protonation microconstants and pair-interactivity parameters of the dibasic 3-O-haptens.
logkN logkC logkNC logk
C
N logEC;N
2-(Morphin-3-O-yl)acetic acid (9) 8.32 3.04 8.22 2.94 0.10
2-(Oxymorphon-3-O-yl)acetic acid (10) 9.00 2.99 8.87 2.86 0.13
2-(Naloxon-3-O-yl)acetic acid (11) 8.35 3.05 8.23 2.93 0.12
2-(Naltrexon-3-O-yl)acetic acid (12) 9.28 3.15 9.13 3.00 0.15
Figure 4. The microspecies distribution diagram of 2-(morphin-
3-O-yl)acetic acid.
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comparison of the oxymorphone-morphine pair
shows that the hydroxy group at C-14 increases the
basicity of the nitrogen atom, despite the presence of
the electron withdrawing keto group. Intramolecular
hydrogen bonding between the tertiary amino and
hydroxy groups partly accounts for the increased
basicity of the amino group. Saturation of the C7–C8
double bond also contributes to the higher amino
basicity of oxymorphone, as it increases the electron
density around the nitrogen atom.
The carboxylic acids show a higher amino basicity
than their ester derivatives because the former are
predominantly in their negatively charged carboxy-
late form at the pH of amino protonation, whereas
the uncharged ester groups exert a strong electron
withdrawing effect. The logEC,N pair-interactivity
parameters are very similar and very small in each
compound, because the two groups lie far away in
terms of covalent bonds. Our results provide another
proof that the pair-interactivity parameter is a
relatively invariant quantity and is influenced to a
lesser extent by electron withdrawing effects of other
sites than the microscopic protonation constants.[23]
Conclusions
Modification of morphine at C-3 position changes not
only the analgesic activity of the molecule, but also
gives the opportunity for further reactions. The 3-OH
derivatives (morphine, oxymorphone, naloxone, nal-
trexone) containing a free carboxy group are haptens
by definition. Although the functionalization of the
C-3 hydroxy group leads to decreased analgesic
effects and the 3-O-morphine haptens are not
suitable for vaccine against drug abuse, these deriva-
tives are excellent candidates for selective determi-
nation of morphine alkaloids in body fluids, using
various immunoassays (radioimmunoassay, enzyme
immunoassay).
Treating the phenolic hydroxy group containing
morphine derivatives with ethyl bromo- or chloroace-
tate led us to the intermediate 3-O-functionalized
esters. Hydrolyzing them in alkaline solution and
adjusting the pH with hydrochloric acid yielded the
desired HCl salts of 3-O-haptens, namely 2-(morphin-
3-O-yl)acetic acid, 2-(oxymorphon-3-O-yl)acetic acid,
2-(naloxon-3-O-yl)acetic acid and 2-(naltrexon-3-O-yl)
acetic acid. Previously only ethyl 2-(morphin-3-O-yl)
acetic acid (3-O-carboxymethylmorphine ethyl ester)
and 2-(morphin-3-O-yl)acetic acid HCl were synthe-
sized, but not fully characterized, all of the other
compounds, to the best of our knowledge are
synthesized and characterized/described for the first
time (including the aforementioned two molecules,
too). In addition, these carboxy group containing
derivatives show structural similarity to the important
metabolite morphine-3-glucuronide. Thus, the proto-
nation macro- and microconstants of these novel
compounds were determined, too.
Experimental Section
General Information
The reagents and indicator molecules were pur-
chased from Sigma–Aldrich (St. Louis, MO, USA) and
Alfa Aesar (Haverhill, MA, USA) and used without
further purification. Solvents were freshly distilled
prior to use and were dried over anhydrous Na2SO4.
1H- and 13C-NMR spectra were recorded on a 600-
MHz Varian VNMRS spectrometer (Varian, Inc., NMR
Systems, Palo Alto, CA, USA, Varian is now part of
Agilent Technologies) in (D6)DMSO or D2O solutions;
δ is given in ppm relative to (D6)DMSO and DSS as
internal standard, retrospective. 1H- and 13C-NMR
signals were assigned on the basis of one- and two-
dimensional hetero-nuclear experiments (gHMBCAD
and gHSQCAD). Melting points were taken on a Stuart
SMP-3 apparatus (Global Science NZ Ltd., Auckland,
New Zealand). The high-resolution accurate masses
were determined with a Dionex Ultimate 3000 UHPLC
system hyphenated with an Orbitrap Q Exactive
Focus Mass Spectrometer equipped with electrospray
ionization (ESI) (Thermo Fischer Scientific, Waltham,
MA, USA). IR spectra were recorded with Perkin Elmer
FT-IT Spectrometer, Spectrum 2000 Diode Pumped
Nd:YAG Laser. To determine the molar ellipticity Jasco
J-720 Spectropolarimeter (Jasco Corp., Tokyo, Japan)
was used (range 170–800 nm, light source: 450 W
xenon lamp, water cool) with 50 nm/min record, 1 s
response and 3 times accumulation. Reaction prog-
ress was observed by thin-layer chromatography on
commercial silica gel plates (Merck silica gel F254 on
aluminum sheets, Darmstadt, Germany), by using
different mobile phases. For column chromatography,
Kieselgel 60 (particle size 0.040–0.063 mm, ordered
from VWR Chemicals, Radnor, PA, USA) was em-
ployed. The indicator molecules for the NMR-pH
titrations (sodium acetate, chloroacetic acid and
dichloroacetic acid) were from Sigma-Aldrich, the
deuterated solvent D2O from VWR International.
Other chemicals of analytical grade were obtained
from commercial suppliers and used without further
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purification. Bidistilled water was used for all solu-
tions.
NMR-pH Titrations
All NMR measurements were performed on a Varian
VNMRS spectrometer (600 MHz for 1H). Spectra were
recorded at 25 °C. The water signal was suppressed
by presaturation.[25] Spectra were processed using
VNMRj 3.2a software. Initial pH values were read on a
Metrohm 2.780.0010 precision pH meter with a
6.0258.600 Unitrode glass Pt 1000 electrode (Met-
rohm AG, Herisau, Switzerland). For the analysis of
NMR titration curves of proton chemical shifts versus
pH, the software Origin Pro 8 (OriginLab Corp.,
Northampton, MA, USA) was used.[26] Titrations were
carried out the same way as in our previous
publication.[19]
pH-Potentiometric Titrations
A 716 DMS Titrino automatic titrator (Metrohm) with
a Metrohm 6.0234.110 combined pH glass electrode
was used for the potentiometric titrations, under
automatic PC (personal computer) control. Non-linear
parameter fitting with Origin 8 provided the proto-
nation constants from the volume differences.[27] The
method of measurements was identical to our
previous work.[19]
3-O-hapten Ester Synthesis
Ethyl 2-(morphin-3-O-yl)acetate (5): Metallic sodium
(0.16 g, 6.96 mmol) was dissolved in absolute ethanol
(30 mL), morphine hydrochloride salt (1.00 g,
3.11 mmol) was added to the solution and treated
with ethyl bromoacetate (0.41 mL, 3.73 mmol). The
mixture was stirred and refluxed for 6 h. It was
monitored by TLC. After conversion, the inorganic
salts were filtered and the solvent was evaporated.
The crude product was purified by column chroma-
tography using chloroform/methanol 9 : 1. Yield: 62%
Ethyl 2-(oxymorphon-3-O-yl)acetate (6): Oxymor-
phone base (0.50 g, 1.66 mmol) was dissolved in
acetone (30 mL). In the presence of potassium
carbonate (0.37 g, 2.68 mmol) and potassium iodide
(0.40 g, 2.41 mmol) the mixture was treated with
ethyl chloroacetate (0.25 mL, 2.34 mmol). After stir-
ring and refluxing for 12 h the solvent was evapo-
rated and the residue was suspended with brine.
Then it was extracted 2 times with chloroform
(25 mL), the organic layers were unified and dried
over sodium sulfate. On TLC only one spot was
observed (chloroform/acetone/diethylamine 5 : 4 : 1).
The salts were filtered and the chloroform was
evaporated. Yield: 70%
Ethyl 2-(naloxon-3-O-yl)acetate (7): Naloxone base
(0.80 g, 2.44 mmol) was dissolved in acetone (25 mL).
In the presence of potassium carbonate (0.42 g,
3.04 mmol) and potassium iodide (0.50 g, 3.01 mmol),
the mixture was treated with ethyl chloroacetate
(0.32 mL, 3.00 mmol). After stirring and refluxing for
12 h, the inorganic salts were filtered and the solvent
was evaporated. The crude product was purified with
column chromatography by using chloroform/meth-
anol 9 : 1. Yield: 67%
Ethyl 2-(naltrexon-3-O-yl)acetate (8): Naltrexone
base (0.34 g, 1.00 mmol) was dissolved in acetone
(20 mL) and the solution was treated with ethyl
bromoacetate (0.13 mL, 1.20 mmol) in the presence
of potassium carbonate (0.69 g, 5.00 mmol). The
mixture was stirred and refluxed for 12 h. The
conversion was followed by TLC. The inorganic salts
were filtered and the solvent was evaporated. The
crude product was purified with column chromatog-
raphy by using chloroform/methanol 9 : 1. Yield: 83%
3-O-hapten Ester Hydrolysis
Every ester was hydrolyzed by following the same
general procedure. The esters were dissolved in a
minimal amount of ethanol and the solutions were
stirred with 0.1 M sodium hydroxide for 30–60 min at
60 °C. The pH was set to 2–3 with diluted
hydrochloric acid and the solvent was evaporated. In
every case the 3-O-hapten hydrochloride salts were
obtained.
2-(Morphin-3-O-yl)acetic acid HCl (9): (5) (0.13 g,
0.35 mmol) was dissolved in ethanol (0.1–0.2 mL) and
treated with sodium hydroxide solution (3.50 mL).
Yield: 70%
2-(Oxymorphon-3-O-yl)acetic acid HCl (10): (6)
(0.10 g, 0.26 mmol) was dissolved in ethanol (0.1–
0.2 mL) and treated with sodium hydroxide solution
(2.60 mL). Yield: 97%
2-(Naloxon-3-O-yl)acetic acid HCl (11): (7) (0.14 g,
0.33 mmol) was dissolved in ethanol (0.1–0.2 mL) and
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treated with sodium hydroxide solution (3.30 mL).
Yield: 80%.
2-(Naltrexon-3-O-yl)acetic acid HCl (12): (8) (0.10 g,
0.24 mmol) was dissolved in ethanol (0.1–0.2 mL) and
treated with sodium hydroxide solution (2.40 mL).
Yield: 98%
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